ProCE Banner Events

Share

Contemporary and Future Strategies in Myelofibrosis: Applying New Evidence to Personalize Care

Join us for this live, CME-certified symposium featuring an expert discussion of current best practices and recent and emerging data in treating patients with myelofibrosis. This activity will feature interactive patient case scenarios and dynamic question and answer sessions. Sign up now!

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

This event has expired. No longer available for credits.

Credits Available

1.5

Who Should Attend

This program is intended for hematologists/oncologists and other healthcare professionals treating patients with myelofibrosis.

Time and location

Friday, June 02, 2023

7:00 PM - 8:30 PM Central Time (CT)

In-personVirtual

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Salon A 1

Agenda

Registration & Dinner: 6:30 - 7:00 PM CT

Symposium: 7:00 - 8:30 PM CT

  • Overview of MF
  • Managing Newly Diagnosed Myelofibrosis
    • Managing treatment-naive MF and MF with no ruxolitinib failure
    • Challenging cases in intermediate-risk and high-risk MF
    • Recognizing patterns of first-line treatment failure in patients with MF
  • Second-line Treatment Options After First-line Failure
    • Including a discussion of emerging agents and relevant clinical trials
  • Partnering With Patients for Improved Outcomes and Quality of Life and Managing Disease-Related and Treatment-Related Symptoms
  • Clinical Trial Spotlight of Key Abstracts at ASCO 2023
  • Audience Question and Answer Session

Location

Venue Name

Hilton Chicago

Address

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Room Name

Salon A 1

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge, confidence, competence, and performance in using evidence-based and guideline-directed best practices in caring for patients with myelofibrosis.

Target Audience
This program is intended for hematologists/oncologists and other healthcare professionals treating patients with myelofibrosis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Incorporate available and emerging therapeutic strategies into the best-practice management of first-line therapy for patients with MF based on available data and expert recommendations, taking risk stratification, molecular features, cytogenetics, and symptom burden
  • Appraise available and emerging clinical trial findings with novel agent for patients with MF, including those with disease-related anemia or for those with MF and severe thrombocytopenia
  • Recognize the symptoms and patterns of suboptimal first-line treatment response in patients with MF, including treatment intolerance and treatment resistance
  • Plan evidence-based therapeutic strategies for patients with MF and suboptimal response to first-line JAK inhibitor therapy
  • Assess the tolerability profiles of current and emerging MF therapies and formulate an adverse-effect management plan to support quality of life and continuation of treatment
  • Recall new data with agents and strategies currently under investigation to aid discussions of ongoing trial opportunities with eligible patients

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

This educational activity is supported by AbbVie, Inc., CTI BioPharma, GSK, and Incyte Corporation.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, competence, and performance in using evidence-based and guideline-directed best practices in caring for patients with myelofibrosis.

Contact Information

For customer support please click here.

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.